Cirrus Logic (NASDAQ:CRUS) Might Have The Makings Of A Multi-Bagger

Simply Wall StSep 28 08:30 ET

At US$123, Is Cirrus Logic, Inc. (NASDAQ:CRUS) Worth Looking At Closely?

Yahoo FinanceSep 23 06:40 ET

CIRRUS: Interim Report 2024

HKEXSep 19 04:32 ET · Announcements

Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET

BenzingaSep 17 16:02 ET

Express News | Watching Shares Of Edgewise Therapeutics; Traders Circulating Undated Report; Edgewise Therapeutics Launches CIRRUS-HCM Trial To Assess Safety And Effects Of EDG-7500, A Novel Cardiac Sarcomere Modulator For Hypertrophic Cardiomyopathy

BenzingaSep 17 13:46 ET

Looking Into Cirrus Logic's Recent Short Interest

BenzingaSep 12 12:45 ET